Stefanos Theoharis
CEO,
OneChain Immunotherapeutics
Sessions
-
08-Sep-2026Theatre 2Spotlight: A new lentiviral vector for in vivo CAR-T with high specificity and efficacy for multi-immune cell targeting
-
08-Sep-2026Theatre 1Panel: The in vivo inflection: From breakthrough to clinical momentum, how far and how fast can this wave go?
-
09-Sep-2026Theatre 1Panel: Access is the real innovation: How Europe turns breakthroughs into therapies patients can actually receive